TransCode Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	6.38	7.15	8.4	3.4	0.44	0.23
Research & Development	11.43	12.26	10.23	2.75	0.28	0.23
Operating Expenses	17.81	19.42	18.63	6.15	0.73	0.46
Operating Income	-17.81	-19.42	-18.63	-6.15	-0.73	-0.46
Interest Expense / Income	0.07	0.06	0.03	0.1	0.39	0.16
Other Expense / Income	-0.82	-0.93	-1.1	0.6	1.22	-0.01
Pretax Income	-17.06	-18.55	-17.56	-6.84	-2.34	-0.61
Net Income	-17.06	-18.55	-17.56	-6.84	-2.34	-0.61
Shares Outstanding (Basic)	5	0	0	0	0	0
Shares Outstanding (Diluted)	5	0	0	0	0	0
Shares Change	27557.71%	1003.48%	54.03%	81.74%	-	-
EPS (Basic)	-229.08	-103.61	-1082.79	-648.00	-408.00	-104.00
EPS (Diluted)	-229.08	-103.61	-1082.79	-648.00	-408.00	-104.00
Free Cash Flow	-17.52	-18.11	-15.86	-5.52	-0.49	-0.51
Free Cash Flow Per Share	-3.41	-101.17	-977.90	-523.98	-85.06	-87.75
EBITDA	-16.43	-17.97	-17.43	-6.71	-1.95	-0.45
Depreciation & Amortization	0.56	0.52	0.1	0.04	0	0
EBIT	-16.99	-18.49	-17.53	-6.75	-1.95	-0.45

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).